Myelofibrosis treatment, myelofibrosis management

Condition analysis:
Hi, dear. I have gone through your question. I can understand your concern. Treatment of myelofibrosis depends on risk category.

Stem cell transplantation is the only definite treatment but it has many risk and other problems.

So largely treatment based on supportive care.

Falic acid, allopurinol, blood transfusion, hydroxyurea etc can be given as supportive treatment.

Ruxolitinib is newer drug which can be helpful and used frequently nowadays.

These are the main treatment options. Consult your doctor and discuss with him regarding this.

Hope I have answered your question, if you have doubt then I will be happy to answer. Thanks for using health care magic. Wish you a very good health.

Instructions:
Treatments that target gene mutations
Researchers are working to develop medications that target the JAK2 gene mutation that's thought to be responsible for myelofibrosis.

The first of these medications approved by the Food and Drug Administration is ruxolitinib (Jakafi). Ruxolitinib and the other medications being developed and tested in clinical trials have been helpful in decreasing enlarged spleens and reducing symptoms associated with myelofibrosis.

It's not yet clear whether these medications can help people with myelofibrosis live longer. But preliminary indications from clinical trials show promise.

Ruxolitinib works by stopping the action of all JAK-related genes in the body, including those found in both healthy and diseased cells. Because healthy cells are affected, side effects may occur, such as bleeding, infection, bruising, dizziness and headaches.